Fortune Business Insights foresees the pharmaceutical segment to dominate the global epigenomics market on account of the increasing prevalence of chronic diseases such as cancer. According to the World Health Organization (WHO), by the end of 2025, the number of cancer patients will reach 21,471,996.
The increasing prevalence of chronic diseases such as cancer is helping the global epigenomics market to emerge with remarkable market figures, finds Fortune Business Insights in their new study. The study is titled, “Epigenomics Market: Global Market Analysis, Insights, and Forecasts, 2019 – 2026.” An important factor propelling this market is the rise in number of chronic diseases and their needful treatment worldwide.
Some of the major companies that are present in the Global Epigenomics Market
- Novartis AG
- Abbott Laboratories
- Abcam plc
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Zymo Research Corporation
- Illumina Inc.
- Agilent Technologies Inc
- Epizyme Inc.
- Boehringer Ingelheim International GmbH
- Bayer AG
- Epigenomics and other players.
This is a key factor impelling researchers for developing novel epigenomics modulators for treating, and augmenting the growth of the pharmaceuticals segment in the market for epigenomics during the forecast duration. Besides this, the rise in research and development programs for exploiting epigenetics alteration for treating cancer and other chronic diseases will help the pharmaceutical segment to generate more revenue in the coming years.
Upgraded Therapeutic Procedures to Fuel Demand for Epigenomics in Market
Geographically, the global epigenomics market is anticipated to be dominated by North America owing to the presence of better healthcare infrastructure and proper medical facilities. Besides this, the availability of upgraded therapeutic machinery and supportive reimbursement policies for people, especially in developed nations such as Canada and the U.S. are also helping the market in the region gain dominance and continue dominating in the years to come.
Asia Pacific, on the other hand is prognosticated to show faster growth rates on account of increasing disposable income of people and introduction and implementation of advanced technology in medical technology and treatment facilities. The developing nations are trying to impose new medication therapies for better outcomes.